1049706-72-0

Usage

Preparation

3-bromo-4-methyl-5-nitropyridin-2-ol synthesis: 4-Methyl-5-nitropyridin-2-ol (104.5 g, 0.68 mol) was suspended in AcOH (1000 mL) and bromine (208 mL, 6 eq) was added dropwise in 1.5 h. The mixture was stirred for 5 min, the poured into icewater (2000 mL) and stirred for 1 h. The resulting suspension was filtered and the residue was washed with water (3*100 mL), dried in vacuo and then stripped with toluene (2*500 mL) and CH3CN (500 mL). This afforded 3-bromo-4-methyl-5-nitropyridin-2-ol as a yellow solid (143.8 g, 91%).

Upstream product

• 21901-41-7 4-methyl-5-nitropyridin-2(1H)-one 
• 21901-41-7 2-hydroxy-4-methyl-5-nitropyridine 

Downstream Products

• 1150618-07-7 C₈H₇BrN₂O₄ 
• 1049706-74-2 3-bromo-2-(4-chloro-3-trifluoromethylphenoxy)-4-methyl-5-nitropyridine 

Relevant academic research and scientific papers

Discovery of [1,2,4]Triazolo[1,5- a]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse Agonists

The retinoic acid receptor-related orphan nuclear receptor γt (RORγt), a promising therapeutic target, is a major transcription factor of genes related to psoriasis pathogenesis such as interleukin (IL)-17A, IL-22, and IL-23R. On the basis of the X-ray cocrystal structure of RORγt with 1a, an analogue of the known piperazine RORγt inverse agonist 1, triazolopyridine derivatives of 1 were designed and synthesized, and analogue 3a was found to be a potent RORγt inverse agonist. Structure-activity relationship studies on 3a, focusing on the treatment of its metabolically unstable cyclopentyl ring and the central piperazine core, led to a novel analogue, namely, 6-methyl-N-(7-methyl-8-(((2S,4S)-2-methyl-1-(4,4,4-trifluoro-3-(trifluoromethyl)butanoyl)piperidin-4-yl)oxy)[1,2,4]triazolo[1,5-a]pyridin-6-yl)nicotinamide (5a), which exhibited strong RORγt inhibitory activity and a favorable pharmacokinetic profile. Moreover, the in vitro and in vivo evaluation of 5a in a human whole-blood assay and a mouse IL-18/23-induced cytokine expression model revealed its robust and dose-dependent inhibitory effect on IL-17A production.

6-AZAINDOLE COMPOUNDS

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS

The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.

Discovery of an HIV integrase inhibitor with an excellent resistance profile

In the present article, we describe SAR studies within a series of N-hydroxy-dihydronaphthyridinone HIV integrase inhibitors that led to a candidate compound, PF-4776548, of high potency and with an excellent resistance profile. Uncertainties around the h

NOVEL MICROBIOCIDES

Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides.